Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Exactus, Inc. (OTC: EXDI).

Full DD Report for EXDI

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.0150.0230.0230.01560,200
2018-12-070.0270.0265950.0270.025327,780
2018-12-060.0380.0250.0380.025153,100
2018-12-05N/A0.044N/AN/A0
2018-12-04N/A0.044N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-3050,00053,50093.4579Short
2018-11-2043,514121,15035.9175Short
2018-11-19170,775367,32046.4922Short
2018-11-1577,900100,80077.2817Short
2018-11-1320,00040,04049.9500Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EXDI.


About Exactus, Inc. (OTC: EXDI)

Logo for Exactus, Inc. (OTC: EXDI)

Exactus, Inc. EXDI is a publicly traded life science company based in Richmond, Virginia that is developing and commercializing Point of Care POC diagnostics for measuring proteolytic enzymes in the blood.

 

Contact Information

 

 

Current Management

  • Philip J. Young / CEO, President
    • Mr. Young is a Founder of Exactus and serves as its Chairman, President and Chief Executive Officer. He has served as a Director and Executive Officer for public and private companies for the past years where has had created significant shareholder value, built integrated commercial operations and directed successful M amp A transactions. From October through December , he served as President, Chief Executive Officer and Director for AmpliPhi Biosciences, a global biopharmaceutical company, where he completed a transformational restructuring, collaborations and financings. He was the President, CEO and Director of Osteologix, Inc. from April through March , where he established corporate offices in Ireland after successfully completing a global divestiture of its lead program. Prior to joining Osteologix, Mr. Young served as an Executive Vice President and Chief Business Officer for Insmed Inc., a publicly traded biotechnology company where he directed all financing, commercial and corporate communications activities. Prior to Insmed Inc., Mr. Young held executive positions at Elan, Neurex, and Pharmacia Corporations. Mr. Young started his management career in the biopharmaceutical industry at Genentech Inc. where he was responsible for their cardiovascular and endocrine product launches sales and marketing.
  • Timothy Ryan / EVP
    • Mr. Ryan is a Founder of Exactus. He serves as Executive Vice President and on our Board of Directors. For the past eight years, he has been a Managing Director, of The Shoreham Group, a Life Sciences Advisory and Investor Relations firm. In , Mr. Ryan led the leveraged buyout of Merrill Industries, a manufacturer and distributor of packaging products. He currently serves on its board of directors. For the five years preceding Shoreham s formation in , he was a Senior Vice President of the Trout Group, a Life Sciences Advisory and Investor Relations firm. Prior to that, he was the Chairman of the Board of Stracq, Inc., an acquisition vehicle where he led the buyout of a healthcare ingredient company, Stryka Botanics, from Chapter bankruptcy.
  • Kelley A. Wendt / CFO
    • Ms. Wendt, serves as our Chief Financial Officer and Treasurer. From December through September , Ms. Wendt served as the Chief Financial Officer and consultant for Ampliphi BioSciences, a global biopharmaceutical company. Prior to joining AmpliPhi, she served as the Chief Financial Officer for Osteologix, Inc. Prior to joining Osteologix, Ms. Wendt served as the Chief Financial Officer for Crop Life America, a global chemical industry trade organization, from to . She is the former Controller for Sheltering Arms Hospitals, a rehabilitation hospital company with nine facilities across the Richmond, Virginia region. Her preexecutive experience consists of several regional and national public accounting firms, primarily in audit and consulting roles.
  • James R. Erickson / CBO
    • James R. Erickson, Ph.D, serves as our Chief Business Officer. Prior to joining Exactus, Dr. Erickson served as a Senior Transaction Advisor at Ferghana Partners, a healthcare investment bank focusing on financings, M amp A and corporate partnering in the diagnostic and therapeutic sectors, a position he held since October . Previously, Dr. Erickson served as Chief Executive Officer of BayPoint Biosystems, Inc., a proteomic company focused on commercializing diagnostics/research toolsoriented technology from the M.D. Anderson Cancer Center, from December to August .
  • Philip J. Young / Chairman
    • Mr. Young is a Founder of Exactus and serves as its Chairman, President and Chief Executive Officer. He has served as a Director and Executive Officer for public and private companies for the past years where has had created significant shareholder value, built integrated commercial operations and directed successful M amp A transactions. From October through December , he served as President, Chief Executive Officer and Director for AmpliPhi Biosciences, a global biopharmaceutical company, where he completed a transformational restructuring, collaborations and financings. He was the President, CEO and Director of Osteologix, Inc. from April through March , where he established corporate offices in Ireland after successfully completing a global divestiture of its lead program. Prior to joining Osteologix, Mr. Young served as an Executive Vice President and Chief Business Officer for Insmed Inc., a publicly traded biotechnology company where he directed all financing, commercial and corporate communications activities. Prior to Insmed Inc., Mr. Young held executive positions at Elan, Neurex, and Pharmacia Corporations. Mr. Young started his management career in the biopharmaceutical industry at Genentech Inc. where he was responsible for their cardiovascular and endocrine product launches sales and marketing.
  • Timothy Ryan / Mr. Ryan is a Founder of Exactus. He serves as Executive Vice President and on our Board of Directors. For the past eight years, he has been a Managing Director, of The Shoreham Group, a Life Sciences Advisory and Investor Relations firm. In , Mr. Ryan led the leveraged buyout of Merrill Industries, a manufacturer and distributor of packaging products. He currently serves on its board of directors. For the five years preceding Shoreham s formation in , he was a Senior Vice President of the Trout Group, a Life Sciences Advisory and Investor Relations firm. Prior to that, he was the Chairman of the Board of Stracq, Inc., an acquisition vehicle where he led the buyout of a healthcare ingredient company, Stryka Botanics, from Chapter bankruptcy.

Current Share Structure

  • Market Cap: $4,414,864 - 03/09/2018
  • Authorized: 200,000,000 - 03/06/2018
  • Issue and Outstanding: 36,790,537 - 03/06/2018
  • Float: 11,730,018 - 11/07/2016

 


Recent Filings from (OTC: EXDI)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 22 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 24 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 20 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 15 2017

 

 


Daily Technical Chart for (OTC: EXDI)

Daily Technical Chart for (OTC: EXDI)


Stay tuned for daily updates and more on (OTC: EXDI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: EXDI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EXDI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EXDI and does not buy, sell, or trade any shares of EXDI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/